GlassScriptPhysician profile
John J Zhang
NPI 1871666453
$10,767.94
in general payments reported to CMS, 2019-2025
14 companies · $70.04 in 2025
The $70.04 reported for 2025 was less than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $59.86 · 2021: $2,364 · 2022: $49.21 · 2023: $41.22 · 2024: $7,568 · 2025: $70.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $7,536 · Food and Beverage: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $7,535.93 |
| Food and Beverage | $143.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $7,535.93 | 2024 | Oes Hysterofiberscope |
| Vitrolife INC. | $2,335.30 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $329.03 | 2019-2022 | |
| Csa Medical, INC | $178.16 | 2019 | |
| Merck Sharp & Dohme LLC | $165.84 | 2021 | |
| Coopersurgical, INC. | $52.75 | 2023-2025 | Stripper, Origio Sequential Fert |
| Xeris Pharmaceuticals, INC. | $48.04 | 2024-2025 | Gvoke Hypopen |
| Solventum Corporation | $21.44 | 2025 | V.A.C.Ulta, V.A.C. Veraflo, Prevena |
| Organon LLC | $20.92 | 2023 | |
| Amgen INC. | $19.76 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.40 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.39 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.01 | 2019 | |
| Emd Serono, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.